Tcg Crossover Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Tcg Crossover Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $5.25 Million - $8.68 Million	-30,634 Reduced 17.03%	149,283 $39.9 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $4.38 Million - $6.77 Million	30,000 Added 20.01%	179,917 $26.3 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $31.9 Million - $42.4 Million	-138,137 Reduced 47.96%	149,917 $36.3 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $15.1 Million - $76.5 Million	258,054 Added 860.18%	288,054 $83.6 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $1.82 Million - $2.39 Million	30,000 New	30,000 $1.95 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.37B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Tcg Crossover Management, LLC with notifications on news.